Trial date set for Teva's generic COPAXONE patent infringement litigation against Momenta

Mar 2 2011

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that the United States District Court for the Southern District of New York has set a trial date of September 7, 2011 in the Company's ongoing patent infringement litigation against Momenta Pharmaceuticals, Inc./Sandoz Inc. and Mylan Pharmaceuticals, Inc./Mylan Inc./Natco Pharma Ltd. regarding their purported generic versions of COPAXONE® (glatiramer acetate injection).

"We are very pleased to have a trial date as we are confident we will prevail in this litigation," said Richard Egosi, Teva's Chief Legal Officer. "Teva remains committed to vigorously defending its intellectual property rights against infringement."

Source:

Teva Pharmaceutical Industries Ltd.

Posted in: Medical Patent News | Pharmaceutical News

Tags: , , , , , ,

Comments (0)

Suggested Reading

The development of a machine-learned scoring function of human preference in the context of early drug discovery campaigns
From Cells to Drugs: How Cell Painting is Transforming Drug Discovery
Study identifies common skin bacterium as previously unknown culprit behind itch
Perioperative durvalumab may change standard-of-care for patients with resectable lung cancer
AI-designed drug candidate shows promise for gastric acid inhibition
Exonate announces successful completion of Phase Ib/IIa trial in diabetic macular oedema
New drug shows promise for epilepsy patients with resistant seizures
Nitrite analysis in pharmaceuticals: monitoring a precursor to nitrosamine

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »
You might also like...
MD Anderson and Jazz Pharmaceuticals collaborate to investigate the potential of zanidatamab in HER2-expressing cancers